drug · small molecule
zasocitinib
Phase 3updated 7mo agoby $TAK TAKEDA PHARMACEUTICAL CO LTD🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 7 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying zasocitinib
- phase3A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
- phase2A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
- phase3Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
- phase3A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis
- phase2A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease
- phase3A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
- phase3A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
- phase2A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
News(10)
- As part of sales reorganization, Novo will cut 215 employees at US HQFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 7h ago
- China's InventisBio delivers competitive TYK2 data in phase 3 psoriasis winA phase 3 trial of InventisBio’s nomelcitinib has hit its primary endpoint, delivering evidence that the TYK2 inhibitor can hold its own against rival psoriasis drugs.fiercebiotech · 18d ago
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 1mo ago
- Takeda’s long-term R&D head announces exit after major pipeline reorganizationA few months after a new CEO stepped up to helm Takeda, the drugmaker will now have to prepare for another leadership change as its long-time R&D head plans his exit.biospace · 2mo ago
- Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successesAndy Plump, M.D., Ph.D., president of research and development at Takeda, is set to leave the company in June.fiercebiotech · 2mo ago
- Schrödinger births new immunology and inflammation biotech, Tectora TherapeuticsSchrödinger announced the launch of new immune disease-focused Tectora Therapeutics, which comes online with a $55 million series A financing round.fiercebiotech · 2mo ago
- Alumis crushed by midstage lupus flop but plots path to phase 3 for TYK2 inhibitorA phase 2b lupus trial of Alumis’ envudeucitinib has missed its primary and secondary endpoints. But the biotech is still moving the TYK2 inhibitor into phase 3 in the autoimmune disease, pointing…fiercebiotech · 2mo ago
- FDA OKs Takeda, Protagonist drug for rare blood cancerThe clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts expect to reach $2 billion or more.biopharma_dive · 2mo ago
- Takeda, Protagonist score broad FDA nod in rare blood cancer, setting up $2B opportunityThe approval of rusfertide—now to be branded Mimrylo—for polycythemia vera marks a key win for Takeda, which now has crossed the FDA finish line for two of three critical product launches slated fo…biospace · 2mo ago
- MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trialMoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.fiercebiotech · 3mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that